{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:21:11Z","timestamp":1791580871280,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T00:00:00Z","timestamp":1717891200000},"content-version":"vor","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003493","name":"Hertie Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003493","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB CRC-TR-128"],"award-info":[{"award-number":["SFB CRC-TR-128"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB CRC-1292"],"award-info":[{"award-number":["SFB CRC-1292"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1080"],"award-info":[{"award-number":["SFB 1080"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.medj.2023.05.001","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T10:58:23Z","timestamp":1685012303000},"page":"361-372.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis"],"prefix":"10.1016","volume":"4","author":[{"given":"Aaron","family":"Schuckmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Zipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9211-5873","authenticated-orcid":false,"given":"Katrin","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2023.05.001_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2023.05.001_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2023.05.001_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1756285615601933","article-title":"The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects","volume":"9","author":"Sorensen","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.medj.2023.05.001_bib4","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2023.05.001_bib5","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.medj.2023.05.001_bib6","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2023.05.001_bib7","doi-asserted-by":"crossref","first-page":"103448","DOI":"10.1016\/j.msard.2021.103448","article-title":"CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: implications for SARS-CoV-2 vaccinations in multiple sclerosis","volume":"57","author":"Baker","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.medj.2023.05.001_bib8","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1177\/1352458519872889","article-title":"Treatment of multiple sclerosis with rituximab: a multicentric Italian-Swiss experience","volume":"26","author":"Zecca","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.medj.2023.05.001_bib9","doi-asserted-by":"crossref","first-page":"e1035","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.medj.2023.05.001_bib10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/13524585211028833","article-title":"Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic","volume":"28","author":"van Lierop","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.medj.2023.05.001_bib11","doi-asserted-by":"crossref","first-page":"117501","DOI":"10.1016\/j.jns.2021.117501","article-title":"Personalizing ocrelizumab treatment in Multiple Sclerosis: what can we learn from Sars-Cov2 pandemic?","volume":"427","author":"Tazza","year":"2021","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.medj.2023.05.001_bib12","doi-asserted-by":"crossref","first-page":"102704","DOI":"10.1016\/j.msard.2020.102704","article-title":"Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness","volume":"48","author":"Barun","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.medj.2023.05.001_bib13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2023.05.001_bib14","unstructured":"German Federal Joint Committee (G-BA): Tragende Gr\u00fcnde zum Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII\u00a0\u2013 Beschl\u00fcsse \u00fcber die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V\u00a0\u2013 ocrelizumab. Available at: https:\/\/www.g-ba.de\/downloads\/40-268-5167\/2018-08-02_AM-RL-XII_Ocrelizumab_D-332_TrG.pdf. (Accessed February 2, 2022)."},{"key":"10.1016\/j.medj.2023.05.001_bib15","doi-asserted-by":"crossref","first-page":"671503","DOI":"10.3389\/fimmu.2021.671503","article-title":"Rituximab associated hypogammaglobulinemia in autoimmune disease","volume":"12","author":"Tieu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2023.05.001_bib16","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1212\/NXI.0000000000001115","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with rituximab","volume":"9","author":"Perriguey","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.medj.2023.05.001_bib17","doi-asserted-by":"crossref","first-page":"e977","DOI":"10.1212\/NXI.0000000000000977","article-title":"Rituximab-induced hypogammaglobulinemia and infections in AQP4 and MOG antibody-associated diseases","volume":"8","author":"Avouac","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.medj.2023.05.001_bib18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40263-021-00810-3","article-title":"Predicting infection risk in multiple sclerosis patients treated with ocrelizumab: a retrospective cohort study","volume":"35","author":"Seery","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.medj.2023.05.001_bib19","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2023.05.001_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2018.02.010","article-title":"Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study","volume":"48","author":"Boleto","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.medj.2023.05.001_bib21","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/rheumatology\/keu194","article-title":"Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis","volume":"53","author":"Besada","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.medj.2023.05.001_bib22","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/rheumatology\/keab626","article-title":"New-onset hypogammaglobulinemia and infectious complications associated with rituximab use in childhood-onset rheumatic diseases","volume":"61","author":"Ong","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.medj.2023.05.001_bib23","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2023.05.001_bib24","doi-asserted-by":"crossref","first-page":"102279","DOI":"10.1016\/j.msard.2020.102279","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis","volume":"44","author":"Baker","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.medj.2023.05.001_bib25","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1177\/13524585211065711","article-title":"Extended dosing of monoclonal antibodies in multiple sclerosis","volume":"28","author":"van Kempen","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.medj.2023.05.001_bib26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1177\/13524585211055593","article-title":"Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-\u201cYes\u201d","volume":"28","author":"Rolfes","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.medj.2023.05.001_bib27","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1177\/13524585211064441","article-title":"Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO","volume":"28","author":"van Kempen","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.medj.2023.05.001_bib28","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2023.05.001_bib29","doi-asserted-by":"crossref","first-page":"103581","DOI":"10.1016\/j.ebiom.2021.103581","article-title":"Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies","volume":"72","author":"Sormani","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.medj.2023.05.001_bib30","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/bcp.14658","article-title":"Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO","volume":"87","author":"Gibiansky","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.medj.2023.05.001_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420987031","article-title":"Health economics of disease-modifying therapy for multiple sclerosis in the United States","volume":"14","author":"Hartung","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.medj.2023.05.001_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.msard.2012.12.001","article-title":"Editors' welcome and a working definition for a multiple sclerosis cure","volume":"2","author":"Banwell","year":"2013","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.medj.2023.05.001_bib33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2023.05.001_bib34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","article-title":"Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study","volume":"8","author":"Havrdova","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2023.05.001_bib35","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/jamaneurol.2014.1895","article-title":"The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis","volume":"71","author":"Cohen","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.medj.2023.05.001_bib36","first-page":"850","article-title":"Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests","volume":"69","author":"Goodkin","year":"1988","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.medj.2023.05.001_bib37","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/1352458509354552","article-title":"Psychometrics and normative data for the multiple sclerosis functional composite: replacing the PASAT with the symbol digit modalities test","volume":"16","author":"Drake","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.medj.2023.05.001_bib38","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.medj.2023.05.001_bib39","doi-asserted-by":"crossref","DOI":"10.3310\/hta13120","article-title":"Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods","volume":"13","author":"Hobart","year":"2009","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.medj.2023.05.001_bib40","doi-asserted-by":"crossref","first-page":"102807","DOI":"10.1016\/j.ebiom.2020.102807","article-title":"Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study","volume":"56","author":"Bittner","year":"2020","journal-title":"EBioMedicine"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634023001411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634023001411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:57:24Z","timestamp":1778921844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634023001411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2666634023001411"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2023.05.001","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2023.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}